Skip to main content
PTGX
NASDAQ Life Sciences

CEO Sells $7.5 Million in Stock After Option Exercise

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
7
Price
$99.95
Mkt Cap
$6.428B
52W Low
$43.2
52W High
$107.84
Market data snapshot near publication time

summarizeSummary

Protagonist Therapeutics' CEO sold $7.5 million in company stock after exercising options, contributing to a recent trend of insider sales despite strong Q1 earnings.


check_boxKey Events

  • CEO Stock Sale

    CEO Dinesh V. Patel sold 75,000 shares of common stock for $7,509,000 at an average price of $100.12 per share.

  • Option Exercise

    The sale followed the exercise of options for 75,000 shares at a strike price of $21.58, valued at $1,618,500.

  • Insider Selling Trend

    This transaction adds to a pattern of insider sales totaling nearly $20 million over the last 90 days, including recent sales by the CFO and a Director.

  • Post-Earnings Sale

    The sale occurred shortly after the company reported a profitable Q1 2026, marking a significant financial turnaround.


auto_awesomeAnalysis

Protagonist Therapeutics' CEO, Dinesh V. Patel, sold $7.5 million worth of common stock after exercising options. This transaction follows recent positive Q1 earnings, and contributes to a broader pattern of insider sales observed over the past 90 days. While exercising options and selling is a common practice for executives to realize gains, the magnitude of the sale by the CEO could be interpreted as profit-taking rather than a strong signal of future growth confidence, especially given the recent financial turnaround.

At the time of this filing, PTGX was trading at $99.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $43.20 to $107.84. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed PTGX - Latest Insights

PTGX
May 12, 2026, 7:28 PM EDT
Filing Type: 4
Importance Score:
7
PTGX
May 11, 2026, 8:25 PM EDT
Filing Type: 4
Importance Score:
8
PTGX
May 05, 2026, 4:28 PM EDT
Source: Reuters
Importance Score:
9
PTGX
May 05, 2026, 4:27 PM EDT
Filing Type: 10-Q
Importance Score:
9
PTGX
May 05, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
9
PTGX
Apr 28, 2026, 4:44 PM EDT
Filing Type: DEF 14A
Importance Score:
7
PTGX
Mar 27, 2026, 7:33 PM EDT
Filing Type: 4
Importance Score:
7
PTGX
Mar 24, 2026, 5:56 PM EDT
Filing Type: 144
Importance Score:
7
PTGX
Feb 25, 2026, 4:28 PM EST
Filing Type: 10-K
Importance Score:
7
PTGX
Feb 25, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8